Gold investors could see a short-term rebound in October due to lower prices, technical support, and seasonal trends, according to strategist Carley Garner. She suggests a tactical bullish trade, expecting gold to rise by 300-400 points but remains bearish on its long-term prospects due to a strong U.S. dollar. Garner recommends cautious trading strategies like micro or one-ounce gold futures and an options trade to limit risk. The potential catalyst for gold's rebound could be stabilization in the U.S. Treasury market, but she warns of significant downside risk if gold falls below $3,900.
Gold's tactical buying opportunity comes amid a market where 83 of 150 US stocks traded on Pluang rose today. For readers following US equities, here is Pluang's market snapshot as of Oct 02, 2026 02:41 WIB: Firy Inc. (FIRY) rose 3.35% with 100% sell orders, Walt Disney Co (DIS) fell 3.19% with 100% buy orders, and Salesforce Inc. (CRM) gained 3.15% with 83% sell orders. This breadth indicates mixed investor sentiment across these stocks.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
